Avalo Therapeutics
(NASDAQ) AVTX
Avalo Therapeutics Financials at a Glance
Market Cap
$610.96M
Revenue (TTM)
$59.00K
Net Income (TTM)
$78.26M
EPS (TTM)
$-6.10
P/E Ratio
-3.75
Dividend
$0.00
Beta (Volatility)
1.12 (Average)
Dividend
$0.00
Beta (Volatility)
1.12 (Average)
Price
$22.87
Volume
5,742,150.86
Open
$22.30
Price
$22.87
Volume
5,742,150.86
Open
$22.30
Previous Close
$22.87
Daily Range
$21.31 - $24.27
52-Week Range
$3.39 - $24.27
Dividend
$0.00
Beta (Volatility)
1.12 (Average)
Price
$22.87
Volume
5,742,150.86
Open
$22.30
Previous Close
$22.87
Daily Range
$21.31 - $24.27
52-Week Range
$3.39 - $24.27
AVTX News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Avalo Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
33
CEO
Garry Arthur Neil, MD
Website
www.avalotx.comHeadquarters
Rockville, MD 20850, US
AVTX Financials
Key Financial Metrics (TTM)
Gross Margin
73%
Operating Margin
-1236%
Net Income Margin
-1326%
Return on Equity
-72%
Return on Capital
-70%
Return on Assets
-67%
Earnings Yield
-26.67%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$610.96M
Shares Outstanding
26.71M
Volume
5.74M
Avg. Volume
1.21M
Financials (TTM)
Gross Profit
$285.00K
Operating Income
$72.92M
EBITDA
$72.92M
Operating Cash Flow
$51.46M
Capital Expenditure
$0.00
Free Cash Flow
$51.46M
Cash & ST Invst.
$98.34M
Total Debt
$2.43M
Avalo Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$59.00K
-69.3%
Gross Profit
$43.00K
-59.0%
Gross Margin
72.88%
N/A
Market Cap
$610.96M
N/A
Market Cap/Employee
$26.56M
N/A
Employees
23
N/A
Net Income
$13.72M
+61.2%
EBITDA
$19.73M
-49.0%
Quarterly Fundamentals
Net Cash
$95.91M
-28.4%
Accounts Receivable
$0.00
-100.0%
Inventory
$0.00
N/A
Long Term Debt
$2.04M
N/A
Short Term Debt
$392.00K
-31.0%
Return on Assets
-67.20%
N/A
Return on Invested Capital
-70.45%
N/A
Free Cash Flow
$14.25M
+5.3%
Operating Cash Flow
$14.25M
+5.3%